Small Cell Lung Cancer Clinical Trials

45 studies are recruiting for small cell lung cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

   This study is designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Highlands Oncology Group, Springdale, Arkansas

   Locations

   229 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT06203210 on ClinicalTrials.gov

2. DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer

   This is a single center pilot, phase Ib study with a safety lead-in evaluating the safety and preliminary efficacy of the EBP inhibitor DSP-0390 in combination with atezolizumab in patients with extensive stage small cell lung cancer (ES-SCLC) whose disease has not progressed after initial inductio…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Washington University School of Medicine, St Louis, Missouri

   Run by

   Washington University School of Medicine

   See if you can join NCT07545954 on ClinicalTrials.gov

3. Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer

   This is an open-label study of NMS-03305293 with Temozolomide (TMZ) in patients with Small Cell Lung Cancer (SCLC). The aim of this study is to determine the safety and tolerability, as well as to evaluate the anti-tumor efficacy and pharmacokinetics of NMS-03305293 in combination with TMZ.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   OSF Saint Francis Medical Center, Peoria, Illinois

   Locations

   3 in total

   Run by

   Nerviano Medical Sciences

   See if you can join NCT06931626 on ClinicalTrials.gov

4. Rapid Autopsy Protocol for Patients With Small Cell Lung Cancer

   This is pilot study to establish a rapid autopsy program in Small Cell Lung Cancer (SCLC) at the Indiana University Simon Comprehensive Cancer Center and outline the components necessary for tumor tissue collection.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana

   Locations

   3 in total

   Run by

   Indiana University

   See if you can join NCT05889546 on ClinicalTrials.gov

5. A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

   This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute at HealthONE, Denver, Colorado

   Locations

   13 in total

   Run by

   IDEAYA Biosciences

   See if you can join NCT07174583 on ClinicalTrials.gov

6. LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)

   This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change i…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of California, Davis, Sacramento, California

   Run by

   University of California, Davis

   See if you can join NCT06103682 on ClinicalTrials.gov

7. Tempus Small Cell Lung Cancer Observational Study (Sculptor)

   The study is a non-interventional evaluation of participants with extensive stage (ES) SCLC who will receive diagnostic and (where possible) post-progression tumor tissue profiling, alongside plasma ctDNA and CTC biomarker profiling during standard of care therapy in both first and second line trea…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Colorado, Aurora, Colorado

   Locations

   11 in total

   Run by

   Tempus AI

   See if you can join NCT05257551 on ClinicalTrials.gov

8. A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain

   The purpose of the study is to see if stereotactic radiosurgery/SRS is an effective treatment for people with a new diagnosis of brain metastases from small cell lung cancer/SCLC.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT05419076 on ClinicalTrials.gov

9. Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

   This is an open-label, non-randomized, single-center, phase II study to evaluate the efficacy, toxicity and, tolerability of pre-specified dose attenuated chemotherapy regimens in lung cancer patients with comorbidities.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Fox Chase Cancer Center, Philadelphia, Pennsylvania

   Run by

   Fox Chase Cancer Center

   See if you can join NCT05800587 on ClinicalTrials.gov

10. Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment

    This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC) patients , Non-Small Cell Lung (NSCLC) and Renal Cell Carcinoma patients…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Alabama at Birmingham, Birmingham, Alabama

    Locations

    7 in total

    Run by

    Advenchen Pharmaceuticals, LLC.

    See if you can join NCT05363280 on ClinicalTrials.gov

11. MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer

    This study has 2 cohorts: MOZART-ES cohort (for extensive-stage SCLC) and MOZART-LS cohort (for limited-stage SCLC). MOZART-ES cohort: Study treatment will consist of a platinum drug (carboplatin or cisplatin per investigator's choice) plus etoposide plus durvalumab plus monalizumab every 3 weeks f…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana

    Locations

    4 in total

    Run by

    Hirva Mamdani

    See if you can join NCT05903092 on ClinicalTrials.gov

12. Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

    The goal of this clinical trial is to learn if investigational drug called SYS6043 works in adults with advanced or metastatic solid tumors that have spread or cannot be treated with standard therapies. The main goals of the study are to understand how safe SYS6043 is, what side effects it may caus…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    BRCR Global, Plantation, Florida

    Locations

    5 in total

    Run by

    Conjupro Biotherapeutics, Inc.

    See if you can join NCT07424547 on ClinicalTrials.gov

13. Phase 2 Study of Fingolimod in Lung Cancers

    This is a single-institution, open-labeled study using fingolimod (FTY720/Gilenya) in patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) who have progressed on chemo-immunotherapy. The study design will be a 6 patient safety lead-in with 2 cohorts of patients for eff…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina

    Run by

    Medical University of South Carolina

    See if you can join NCT06424067 on ClinicalTrials.gov

14. Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

    This this study is for individuals who have treatment-naïve extensive-stage small cell lung cancer (small cell lung cancer that wont respond to treatment). Doctors leading this study hope to learn if combining durvalumab, carboplatin and etoposide with hyofractionated ablative radiation therapy (ra…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Chicago Medicine, Chicago, Illinois

    Locations

    2 in total

    Run by

    University of Chicago

    See if you can join NCT05068232 on ClinicalTrials.gov

15. Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer

    This phase II clinical trial will study the safety and efficacy of onvansertib to treat patients with small cell lung cancer (SCLC) who have either not responded to or are unable to tolerate chemotherapy. Onvansertib is a drug that inhibits polo-like kinase 1 (PLK-1), an enzyme that is over-express…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland

    Locations

    2 in total

    Run by

    University of Maryland, Baltimore

    See if you can join NCT05450965 on ClinicalTrials.gov

16. 7T Brain MRI Scan for Micro-brain Metastasis (microBM) Detection for Patients With Small-cell Lung Cancer (SCLC), Who Decline Prophylactic Cranial Irradiation (PCI)

    Comparison of a 7t MRI to standard of care 1.5t/3t MRI scans to determine if earlier detection of brain metastases are possible on a 7t.

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Missouri, Columbia, Missouri

    Run by

    University of Missouri-Columbia

    See if you can join NCT07175077 on ClinicalTrials.gov

17. A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

    This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Michigan Hospitals, Ann Arbor, Michigan

    Locations

    5 in total

    Run by

    Novelty Nobility, Inc.

    See if you can join NCT06805825 on ClinicalTrials.gov

18. A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer

    This is a multi-center, open-label, Phase 1 clinical study of ZG006 in the US for the treatment of subjects with small cell lung cancer who have failed or are intolerant to available standard treatment. During the dose escalation stage, a standard "3+3" design will be used to assess the MTD/ recomm…

    Stage

    Phase 1

    Ages

    18 to 75

    Site

    Zelgen Site 102, Plantation, Florida

    Locations

    6 in total

    Run by

    Suzhou Zelgen Biopharmaceuticals Co.,Ltd

    See if you can join NCT06592638 on ClinicalTrials.gov

19. Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)

    The goal of this observational study is to understand how genomic and epigenetic factors contribute to resistance against chemo-immunotherapy in adults diagnosed with extensive-stage small cell lung cancer (ES-SCLC) or metastatic large cell neuroendocrine carcinoma (LCNEC). Both ES-SCLC and LCNEC a…

    Stage

    Not phased

    Ages

    18 to 85

    Site

    3rd Department of Medicine, National and Kapodistrian University of Athens, Sotiria Hospital, Athens,

    Locations

    2 in total

    Run by

    Oncology Center of Biochemical Education And Research

    See if you can join NCT06717243 on ClinicalTrials.gov

20. A Multicenter Cancer Biospecimen Collection Study

    This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor biopsy. These specimens and clinical data may be used in subsequent st…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Curebase, San Francisco, California

    Run by

    Cofactor Genomics, Inc.

    See if you can join NCT04510129 on ClinicalTrials.gov